Lol...here was the begining of the ENDO collapse....they sold a lot of stock though.... no overhead other than their lofty salaries...he Dabney ..address the ENDO collapse or whatever you call it now...lmao...Dabney
May 25, 2012
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science, Inc. (CBIS.OB), a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide insight on the upcoming release of its’ new over-the-counter skin and nutraceutical product line to be branded “Phytiva” through its newest venture Phytiva Pharmaceuticals Inc. The Company is working as fast as it can to make its cannabis-based formulations that target critical ailments more widely available through multiple regulatory body guidelines. This approach will allow the Company to release its formulations to multiple markets reaching the maximum amount of people in the shortest time frame across the nation and internationally. To support this cause Cannabis Science has been working with numerous patients who have been documenting their self-medicating treatment process using the cannabis-extracts.
The Company continues to receive a large number of inquiries about current and new product releases and operational updates on its projects in the works. The Company is in the process of updating its website to provide up-to-date timeline information on its projects, product lines, events, conferences and other important corporate and operational information for the public as released for the public.
FDA Initiatives
Cannabis Science is working very close with its previously announced FDA clinical trials consultants to guide the Company through the formal FDA new product release regulatory guidelines. The main steps required to be completed are as follows:
1. Pre-IND meeting with the FDA
*** The Company is currently in this stage and is working close with its’ FDA advisory group towards requesting a pre-IND meeting date. The Company has identified its initial target indication as skin cancer and will present this case to the FDA at the pre-IND meeting.
2. Application filing for IND – Number
Once the Company has presented its case at the pre IND meeting with the FDA and makes any recommended adjustments to its case study, it will then submit its formal application to the FDA for the IND number application.
3. IND – Number assignment
FDA will assign an IND number for the case study once the Company has completed a successful application process. The IND number assignment will give the Company the green light to begin its clinical trials.
4. Begin clinical trials
Once the Company has successfully completed the application process and receives its IND number from the FDA it can then begin formal clinical trials to prove the product viable for general market consumption or use.
5. Successful IND product release
Working within the FDA regulatory procedures is paramount for Cannabis Science. Once it receives full approvals from the FDA on each of its target indications, it will then release its products for patients in need of the treatments for their critical ailments nationwide.
